Apogee Therapeutics to delist Nasdaq; trading suspended Sept. 4, 2026
Apogee Therapeutics notified Nasdaq it has consummated its merger and intends to remove all common stock from Nasdaq, requesting Nasdaq file Form 25 to delist and deregister. Trading will be suspended Sept. 4, 2026.
On September 3, 2026, the company notified Nasdaq of the consummation of its merger and its intent to remove all common stock from Nasdaq, requesting that Nasdaq file a Form 25 to delist and deregister the shares.
Trading will be suspended on September 4, 2026, and the company plans to file a Form…